Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Source :: Legal Monitor Worldwide. November 26, 2020
Publication Year :: 2020
Abstract: Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple Investigational [...]

Subjects :: United States. Food and Drug Administration
Cancer treatment
Talazoparib
Cancer research -- Genetic aspects
Tumors -- Drug therapy -- Genetic aspects
Business, international
Law

Tools